<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074746</url>
  </required_header>
  <id_info>
    <org_study_id>2018-1092</org_study_id>
    <secondary_id>NCI-2019-03536</secondary_id>
    <secondary_id>2018-1092</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04074746</nct_id>
  </id_info>
  <brief_title>Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas</brief_title>
  <official_title>Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of modified umbilical cord blood
      immune cells (natural killer [NK] cells) combined with the antibody AFM13 (AFM13-NK) and
      AFM13 alone in treating patients with CD30 positive Hodgkin lymphoma or non-Hodgkin lymphoma
      that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy
      with monoclonal antibodies, such as AFM13, may help the body's immune system attack the
      cancer, and may interfere with the ability of cancer cells to grow and spread. Giving AFM13
      loaded with NK cells followed by AFM13 alone may kill more cancer cells and decrease cancer
      growth in patients with CD30 positive AFM13-NK Hodgkin and Non-Hodgkin lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To establish the safety and recommended phase II dose of umbilical cord blood (CB)-derived
      natural killer (NK) cells preloaded with the bispecific antibody AFM13 (AFM13-NK), followed
      by intravenous anti-CD30/CD16A monoclonal antibody AFM13 (AFM13) in patients with
      refractory/relapsed CD30-positive lymphoid malignancies.

      SECONDARY OBJECTIVES:

      I. To assess the overall response rate (ORR), complete response (CR) rate and partial
      response (PR) rate.

      II. To evaluate the duration of response. III. To evaluate the event-free survival (EFS)
      rate. IV. To evaluate the overall survival (OS) time. V. To quantify the persistence of
      infused donor CB AFM13-NK cells in the recipient.

      VI. To conduct comprehensive immune reconstitution studies.

      OUTLINE: This is a dose-escalation study of AFM13-NK.

      Patients receive standard of care fludarabine intravenously (IV) over 1 hour and standard of
      care cyclophosphamide IV over 30-60 minutes on days -4 to -2, AFM13-NK IV over 4 hours on day
      0, and then AFM13 IV over 4 hours on days 7, 14, and 21.

      After completion of study treatment, patients are followed up at 28 days, 8 weeks, 100 and
      180 days and then every 3-6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse events will be summarized by dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Distribution will be estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Distribution will be estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by ratio of responses over number of patients with measurable lesions. Logistic regression will be used to assess the association between ORR and disease and demographic covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by ratio of CRs over number of patients with measurable lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response (PR) rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by ratio of PRs over number of patients with measurable lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Time of initial response to disease relapse/progression, assessed up to 2 years</time_frame>
    <description>The evaluation of the duration of the response will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Persistence of infused donor AFM13-NK cells.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>To quantify the persistence of infused donor AFM13-NK cells. Will be summarized with descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The immune reconstitution studies will assessed.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be conducted with the comprehensive immune reconstitution studies and will be summarized with descriptive statistics.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Recurrent Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Classic Hodgkin Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides</condition>
  <condition>Recurrent Peripheral T-Cell Lymphoma</condition>
  <condition>Refractory Anaplastic Large Cell Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Classic Hodgkin Lymphoma</condition>
  <condition>Refractory Mycosis Fungoides</condition>
  <condition>Refractory Peripheral T-Cell Lymphoma</condition>
  <condition>TNFRSF8 Positive</condition>
  <arm_group>
    <arm_group_label>Treatment (AFM13-NK, AFM13)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard of care fludarabine IV over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -4 to -2, AFM13-NK IV over 4 hours on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD30/CD16A Monoclonal Antibody AFM13</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (AFM13-NK, AFM13)</arm_group_label>
    <other_name>AFM13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (AFM13-NK, AFM13)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (AFM13-NK, AFM13)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (AFM13-NK, AFM13)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Genetically Engineered Lymphocyte Therapy</intervention_name>
    <description>Given AFM13-NK cells IV</description>
    <arm_group_label>Treatment (AFM13-NK, AFM13)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of relapsed or refractory classical Hodgkin lymphoma (HL),
             anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma not otherwise
             specified (PTCL-NOS), mycosis fungoides (MF), or B-cell non-Hodgkin lymphoma with a
             pre-enrollment tumor biopsy positive for CD30 by immunohistochemistry at &gt;= 1%.
             Patients with HL, ALCL and MF must be refractory or intolerant to brentuximab vedotin.

          -  Karnofsky performance status &gt;= 60%.

          -  Absolute neutrophil count &gt;= 500/mm^3

          -  Platelet count &gt;= 50,000/mm^3

          -  Serum creatinine clearance &gt;= 50 ml/min, estimated using the Cockcroft-Gault equation.

          -  Serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate
             transaminase (SGPT) =&lt; 3 x upper limit of normal (ULN).

          -  Bilirubin =&lt; 2 x ULN.

          -  Alkaline phosphatase (ALP) =&lt; 2 x ULN.

          -  Forced expiratory volume in 1 second (FEV1) &gt;= 50%

          -  Forced vital capacity (FVC) &gt;= 50%

          -  Carbon monoxide diffusing capability test (DLCO) (corrected for hemoglobin [Hgb]) &gt;=
             50%

          -  Left ventricular ejection fraction &gt;= 40%.

          -  No uncontrolled arrhythmias or symptomatic cardiac disease.

          -  If female of child-bearing potential, must not be pregnant or be breastfeeding and
             required to have a negative urine or serum pregnancy test within 3 days prior to the
             first dose of study drug.

               -  Note: Urine pregnancy tests that cannot be confirmed as negative, require a
                  confirmatory negative serum pregnancy test. In addition, females of childbearing
                  potential must agree use of a highly effective method of contraception for the
                  course of the study from 14 days prior to the first dose of study drug until 60
                  days after the last dose of study drug. Non-childbearing potential is defined as:
                  Postmenopausal: defined as no menses for 12 months without an alternative medical
                  cause. A high follicle-stimulating hormone (FSH) level in the postmenopausal
                  range may be used to confirm post-menopausal state in women not using hormonal
                  contraception or hormonal replacement therapy. In the absence of 12 months of
                  amenorrhea, FSH measurements indicating post-menopausal status must be documented
                  in patient's medical history. Permanently sterile: documented permanent
                  sterilization e.g. hysterectomy, bilateral salpingectomy and bilateral
                  oophorectomy. If male, surgically sterile or agrees to use a highly effective
                  method of contraception, 14 days prior to the first dose of study drug until 60
                  days after the last dose of study drug.

        Exclusion Criteria:

          -  Requirement for systemic corticosteroid therapy &lt; 7 days prior to first dose of study
             drug.

          -  Major surgery &lt; 4 weeks prior to first dose of study drug.

          -  Any other severe or uncontrolled disease or condition which might increase the risk
             associated with study participation.

          -  Any other malignancy known to be active, with the exception of treated cervical
             intra-epithelial neoplasia and non-melanoma skin cancer.

          -  Grade &gt;= 3 non-hematologic toxicity from prior therapy that has not resolved to grade
             =&lt; 2.

          -  Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg
             +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] &gt;= 10,000
             copies/mL, or &gt;= 2,000 IU/mL), or hepatitis C (detectable viral load by hepatitis C
             virus [HCV] ribonucleic acid [RNA] polymerase chain reaction [PCR]).

          -  Active infection requiring parenteral antibiotics.

          -  Human immunodeficiency virus (HIV) infection.

          -  Treatment within prior 4 weeks with any anti-cancer agent, investigational or
             approved.

          -  Active central nervous system (CNS) involvement (untreated parenchymal brain
             metastasis or positive cytology of cerebrospinal fluid).

          -  Life expectancy =&lt; 6 months.

          -  Previous treatment with AFM13.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yago L Nieto</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yago L Nieto</last_name>
    <phone>713-792-8750</phone>
    <email>ynieto@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Yago L. Nieto</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Yago L. Nieto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

